Weigao Orthopaedic(SH:688161)2025-04-29 10:53Financial Performance - The company's operating revenue for Q1 2025 was CNY 290,185,005.08, a decrease of 16.59% compared to the same period last year[3]. - Net profit attributable to shareholders increased by 48.37% to CNY 51,789,016.82, driven by reduced sales expenses and improved operational efficiency[3]. - Basic and diluted earnings per share rose by 44.44% to CNY 0.13, reflecting the increase in net profit attributable to shareholders[3]. - The company reported a net profit excluding non-recurring gains and losses of CNY 49,066,897.23, up 41.95% year-on-year[3]. - The company reported a total profit of ¥68,756,250.20 for Q1 2025, compared to ¥41,477,509.70 in Q1 2024, reflecting a significant growth[16]. - Net profit for Q1 2025 reached ¥52,548,106.68, an increase of 46.5% from ¥35,851,783.23 in Q1 2024[17]. Cash Flow and Investments - The net cash flow from operating activities surged by 272.12% to CNY 55,655,277.16, primarily due to a decrease in cash expenses[3]. - The net cash flow from operating activities was 55,655,277.16, an increase from 14,956,094.00 in the previous period, indicating a significant improvement in operational efficiency[20]. - Cash inflow from investment activities totaled 1,263,184,816.48, compared to 245,450,442.70 previously, reflecting a strong investment recovery[20]. - The net cash flow from investment activities was -56,381,540.12, worsening from -22,137,303.98, suggesting increased investment outflows[20]. - Cash paid for the acquisition of fixed assets was 4,566,356.60, down from 7,587,746.68, indicating a reduction in capital expenditures[20]. - The company received 1,240,000,000.00 in cash from investment recoveries, a significant increase from 240,000,000.00 in the previous period[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,961,933,297.24, a slight increase of 0.28% from the end of the previous year[4]. - Total current assets as of March 31, 2025, amount to ¥4,214,936,608.25, an increase from ¥4,190,993,746.67 as of December 31, 2024[12]. - Total liabilities as of the end of the reporting period were ¥946,135,314.59, down from ¥984,785,361.90[14]. - Total current liabilities decreased to ¥820,801,233.57 from ¥858,444,127.04[13]. - The company’s total assets amounted to ¥4,961,933,297.24, slightly up from ¥4,948,035,237.87[14]. - Total equity attributable to shareholders increased to ¥4,005,308,940.35 from ¥3,953,519,923.53[14]. Research and Development - Total R&D investment amounted to CNY 28,643,022.81, accounting for 9.87% of operating revenue, an increase of 1.38 percentage points year-on-year[4]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,904[8]. - The largest shareholder, Shandong Weigao Group Medical Polymer Co., Ltd., holds 202,500,000 shares, accounting for 50.63% of total shares[8]. Operational Changes - The decline in operating revenue was attributed to the integration of sales models, which impacted revenue generation[6]. - There are no new strategies or significant operational changes reported for the current period[10]. - The company has not disclosed any new product developments or technological advancements in this reporting period[10]. Cost Management - Total operating costs for Q1 2025 were ¥235,809,633.56, down 25.5% from ¥317,060,839.41 in Q1 2024[16]. - The company paid 102,172,206.33 in cash to employees, an increase from 90,090,063.00, reflecting higher labor costs[20].